Cyprus Mail
BusinessHealthcareInternational

AstraZeneca signs $2 bln agreement with Quell to develop cell therapies

astrazenneca

AstraZeneca (AZN.L) said on Friday it had signed an agreement with Quell Therapeutics potentially worth more than $2 billion to develop cell therapies that could cure autoimmune diseases.

The agreement includes developing, manufacturing and commercialising cell therapies that have the potential to be curative in type 1 diabetes and inflammatory bowel disease indications, the drugmaker said in a statement.

UK-based Quell will receive $85 million upfront from AstraZeneca, and is also eligible to receive over $2 billion for further development and commercialisation milestones, the company added.

Follow the Cyprus Mail on Google News

Related Posts

Digital identity, signature coming soon — AI “here to stay”

Kyriacos Nicolaou

€10,000 for SME energy efficiency

Kyriacos Nicolaou

€20 million for new businesses — youth and women key recipients

Kyriacos Nicolaou

Crypto fans count down to bitcoin’s ‘halving’

Reuters News Service

Cyprus Business Now

Kyriacos Nicolaou

Dollar’s dominant reserve currency status to endure, says Morgan Stanley

Reuters News Service